课题基金 / 基金详情

FILGRASTIM SD/01 PTS W/ NON SMALL CELL LUNG CANCER OR THORACIC TUMORS

FILGRASTIM SD/01 PTS W/ NON SMALL CELL LUNG CANCER OR THORACIC TUMORS
FILGRASTIM SD/01 PTS 治疗非小细胞肺癌或胸部肿瘤
批准号：
6304629
负责人：
CHANDRA BELANI
金额：
$0.3万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6304629
关键词：
cis platinum compound clinical research clinical trial phase I colony stimulating factor drug interactions drug screening /evaluation hematopoietic stem cells human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neutrophil nonsmall cell lung cancer paclitaxel pharmacokinetics thorax neoplasm

项目摘要

项目成果

CHANDRA BELANI的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的具体目的是比较非格司亭-SD/01与非格司亭在血液学稳态非小细胞肺癌患者中给药的安全性;并比较非格司亭-SD/01与非格司亭化疗前的药代动力学（PK）;并比较非格司亭-SD/01与非格司亭的药效学（PD）反应（通过中性粒细胞绝对计数（ANC）的变化测量），和外周血中的造血祖细胞水平。 这是一项非格司亭SD/01在接受卡铂和紫杉醇（泰素）治疗的非小细胞肺癌（NSCLC）患者和其他胸部肿瘤患者中的I期开放标签、剂量递增研究。
英文摘要
The specific aims of this study are to compare the safety of Filgrastim-SD/01 to Filgrastim administered to non-small cell lung cancer patients in hematologic steady state; and to compare the pharmacokinetics (PK) of Filgrastim-SD/01 to Filgrastim pre-chemotherapy; and to compare the pharmacodynamic (PD) responses to Filgrastim-SD/01 to Filgrastim as measured by changes in absolute neutrophil count (ANC), and hematopoietic progenitor cell levels in the peripheral blood. This is a phase I open label, dose escalation study of filgrastim SD/01 in non-small cell lung cancer patients (NSCLC) and patients with other thoracic tumors treated with carboplatin and paclitaxel (Taxol).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A PHASE I STUDY IN ADVANCED SOLID MALIGNANCIES (NCI 7967)
CLINICAL TRIAL: PI & PHARMACOKINETIC STUDY OF DRUG FOR SOLID TUMORS & LYMPHOMAS
CLINICAL TRIAL: PI &PHARMACOKINETIC SINGLE AGENT STUDY OF DRUG IN PTS W ADV MALI
Phase I Clinical Trials of Novel Anticancer Agents
海外基金